Rhizen Pharma receives FDA Fast Track Designation for RP6530

 

Alembic Pharma announced that Rhizen Pharmaceuticals S.A.,said the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for RP6530 (tenalisib), the Company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).

“We are pleased that RP6530 (tenalisib) has been granted Fast Track Designation, demonstrating the FDA’s commitment to facilitate the development and expedite the review of our highly selective and orally active dual PI3K delta/gamma inhibitor as an important therapy for patients with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL),” said Swaroop Vakkalanka, Ph.D., Founder & President of Rhizen Pharmaceuticals S.A.

NewsBarons is now active on WhatsApp. To receive news and updates on your handset, please click here and press send to subscribe.

Yash Ved
Yash Ved is a Senior Correspondent at NewsBarons and comes with a decade of experience across leading online and offline publications. A keen observer of the stock index movement, Yash also likes covering Real Estate and the BFSI sector. A financial management and Journalism student, Yash believes learning as a continuous journey and enjoys following the IT and the Pharmaceutical industry and has penned many articles on the subjects.
yash@newsbarons.com
banner4